{{Rsnum
|rsid=7774640
|Gene=PDE7B
|Chromosome=6
|position=135944027
|Orientation=plus
|GMAF=0.3994
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=PDE7B
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 11.5 | 42.5 | 46.0
| HCB | 29.9 | 48.9 | 21.2
| JPT | 14.2 | 45.1 | 40.7
| YRI | 11.6 | 41.8 | 46.6
| ASW | 10.5 | 31.6 | 57.9
| CHB | 29.9 | 48.9 | 21.2
| CHD | 33.9 | 42.2 | 23.9
| GIH | 9.9 | 49.5 | 40.6
| LWK | 12.7 | 47.3 | 40.0
| MEX | 32.8 | 46.6 | 20.7
| MKK | 21.2 | 43.6 | 35.3
| TSI | 12.7 | 49.0 | 38.2
| HapMapRevision=28
}}{{PMID|21383644}} Bioavailability of testosterone enanthate dependent on genetic variation in [[PDE7B]] but not on [[UGT2B17]]. rs7774640(G) had a smaller increase (2.5-fold) in the serum testosterone levels compared with carriers of the A allele (3.9-fold, P=0.0006). In addition, genetic variation in the PDE7B gene significantly influences the testosterone/epitestosterone ratio, a biomarker of testosterone doping.

{{on chip | Affy GenomeWide 6}}